• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Symbyax (olanzapine and fluoxetine HCl capsules)


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- March 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

Sections Modified

PRECAUTIONS

  • General
    • Abnormal Bleeding
    • Hyponatremia
  • Information for Patients
    • Abnormal Bleeding
  • Drug Interactions
    • Drugs that interfere with hemostasis (e.g., NSAIDs, Aspirin, Warfarin)
  • Geriatric Use